Table 3.

Association between serum cholesterol concentration and prostate cancer, placebo arm of the PCPT

Quintile of serum cholesterol concentrationPtrendSerum cholesterol concentration <200 versus ≥200 mg/dL
12345
Total prostate cancer (n)245232252262260
    ORage-adjusted (95% CI) 0.93 (0.76- 1.13)0.89 (0.73-1.09)0.90 (0.74-1.09)1.02 (0.84-1.24)1.00 (Reference)0.370.96 (0.85-1.10)
    ORmultivariable-adjusted* (95% CI)0.94 (0.77-1.15)0.90 (0.74-1.10)0.90 (0.74-1.09)1.03 (0.85-1.25)1.00 (Reference)0.430.97 (0.85-1.11)
Organ-confined disease (n)215209222233245
    ORage-adjusted (95% CI)0.87 (0.71-1.06)0.85 (0.70-1.05)0.84 (0.69-1.03)0.97 (0.79-1.18)1.00 (Reference)0.140.95 (0.83-1.08)
    ORmultivariable-adjusted* (95% CI)0.88 (0.72-1.08)0.86 (0.70-1.06)0.83 (0.68-1.02)0.97 (0.80-1.19)1.00 (Reference)0.170.96 (0.84-1.10)
Gleason 2-6 (n)204185196204204
    ORage-adjusted (95% CI)0.99 (0.80-1.22)0.91 (0.73-1.13)0.89 (0.72-1.10)1.01 (0.82-1.25)1.00 (Reference)0.851.01 (0.88-1.17)
    ORmultivariable-adjusted* (95% CI)1.00 (0.81-1.24)0.91 (0.73-1.13)0.88 (0.71-1.09)1.02 (0.82-1.26)1.00 (Reference)0.941.03 (0.89-1.18)
Gleason 7-10 (n)4147565856
    ORage-adjusted (95% CI)0.72 (0.48-1.09)0.86 (0.57-1.28)0.94 (0.64-1.37)1.07 (0.74-1.57)1.00 (Reference)0.070.79 (0.60-1.03)
    ORmultivariable-adjusted* (95% CI)0.70 (0.46-1.07)0.88 (0.59-1.31)0.95 (0.65-1.39)1.08 (0.74-1.58)1.00 (Reference)0.070.78 (0.60-1.02)
Gleason 7 (n)3441453742
    ORage-adjusted (95% CI)0.80 (0.51-1.27)1.00 (0.64-1.55)1.01 (0.66-1.55)0.91 (0.58-1.43)1.00 (Reference)0.500.93 (0.69-1.24)
    ORmultivariable-adjusted* (95% CI)0.79 (0.49-1.25)1.02 (0.66-1.59)1.01 (0.66-1.56)0.92 (0.59-1.44)1.00 (Reference)0.490.93 (0.69-1.24)
Gleason 8-10 (n)76112114
    ORage-adjusted (95% CI)0.48 (0.19-1.20)0.43 (0.17-1.14)0.73 (0.33-1.62)1.55 (0.78-3.08)1.00 (Reference)0.010.42 (0.22-0.77)
    ORmultivariable-adjusted* (95% CI)0.46 (0.18-1.16)0.45 (0.17-1.17)0.75 (0.33-1.66)1.53 (0.77-3.05)1.00 (Reference)0.010.41 (0.22-0.77)
  • *Adjusted for age, race, family history of prostate cancer, BMI, diabetes, regular aspirin use, and history of heart attack.